Rockefeller Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $198M | Buy |
911,994
+28,350
| +3% | +$6.29M | 0.35% | 56 |
|
|
2025
Q4 | $202M | Buy |
883,644
+81,375
| +10% | +$18.5M | 0.36% | 47 |
|
|
2025
Q3 | $186M | Buy |
802,269
+41,288
| +5% | +$8.41M | 0.36% | 44 |
|
|
2025
Q2 | $141M | Buy |
760,981
+19,098
| +3% | +$3.55M | 0.31% | 59 |
|
|
2025
Q1 | $155M | Sell |
741,883
-21,494
| -3% | -$4.18M | 0.38% | 40 |
|
|
2024
Q4 | $136M | Sell |
763,377
-66,500
| -8% | -$12.2M | 0.35% | 50 |
|
|
2024
Q3 | $164M | Buy |
829,877
+16,917
| +2% | +$3.16M | 0.44% | 35 |
|
|
2024
Q2 | $139M | Buy |
812,960
+14,508
| +2% | +$2.4M | 0.4% | 45 |
|
|
2024
Q1 | $145M | Buy |
798,452
+56,328
| +8% | +$9.71M | 0.42% | 41 |
|
|
2023
Q4 | $115M | Buy |
742,124
+63,616
| +9% | +$9.27M | 0.38% | 52 |
|
|
2023
Q3 | $101M | Buy |
678,508
+47,800
| +8% | +$7.02M | 0.39% | 56 |
|
|
2023
Q2 | $83.3M | Buy |
630,708
+6,220
| +1% | +$912K | 0.32% | 72 |
|
|
2023
Q1 | $99.5M | Sell |
624,488
-16,261
| -3% | -$2.49M | 0.43% | 45 |
|
|
2022
Q4 | $104M | Sell |
640,749
-1,491
| -0.2% | -$229K | 0.52% | 32 |
|
|
2022
Q3 | $86.2M | Buy |
642,240
+137,854
| +27% | +$19.8M | 0.45% | 49 |
|
|
2022
Q2 | $77.3M | Buy |
504,386
+74,757
| +17% | +$11.4M | 0.41% | 56 |
|
|
2022
Q1 | $69.6M | Buy |
429,629
+8,281
| +2% | +$1.2M | 0.34% | 65 |
|
|
2021
Q4 | $57M | Buy |
421,348
+16,429
| +4% | +$1.94M | 0.27% | 85 |
|
|
2021
Q3 | $43.7M | Buy |
404,919
+51,054
| +14% | +$5.83M | 0.23% | 104 |
|
|
2021
Q2 | $39.9M | Buy |
353,865
+61,752
| +21% | +$6.95M | 0.22% | 101 |
|
|
2021
Q1 | $31.6M | Buy |
292,113
+22,357
| +8% | +$2.39M | 0.21% | 114 |
|
|
2020
Q4 | $28.9M | Buy |
269,756
+40,665
| +18% | +$3.91M | 0.22% | 113 |
|
|
2020
Q3 | $20.1M | Buy |
229,091
+38,689
| +20% | +$3.64M | 0.19% | 128 |
|
|
2020
Q2 | $18.7M | Buy |
190,402
+31,350
| +20% | +$2.76M | 0.2% | 118 |
|
|
2020
Q1 | $12.1M | Buy |
159,052
+23,739
| +18% | +$2.02M | 0.16% | 137 |
|
|
2019
Q4 | $12M | Buy |
135,313
+46,515
| +52% | +$3.86M | 0.15% | 138 |
|
|
2019
Q3 | $6.72M | Buy |
88,798
+31,639
| +55% | +$2.17M | 0.09% | 161 |
|
|
2019
Q2 | $4.16M | Sell |
57,159
-4,049
| -7% | -$318K | 0.06% | 176 |
|
|
2019
Q1 | $4.93M | Buy |
61,208
+8,057
| +15% | +$659K | 0.07% | 162 |
|
|
2018
Q4 | $4.9M | Buy |
53,151
+13,156
| +33% | +$1.16M | 0.09% | 132 |
|
|
2018
Q3 | $3.78M | Sell |
39,995
-2,004
| -5% | -$190K | 0.06% | 134 |
|
|
2018
Q2 | $3.89M | Buy |
41,999
+226
| +0.5% | +$22.1K | 0.06% | 136 |
|
|
2018
Q1 | $3.95M | Buy |
+41,773
| New | +$4.59M | 0.07% | 137 |
|
Other funds holding ABBV
VCM
VPM
Rockefeller Capital Management's ABBV Position: Q1 2026 in Review
Rockefeller Capital Management increased its AbbVie (ABBV) stake by 3.2% in Q1 2026, buying an estimated $6.29M and bringing the position to 911,994 shares worth $198M. The position accounts for 0.35% of the portfolio, ranked #56.
Rockefeller Capital Management first reported a position in ABBV in Q1 2018 and has held it in 33 quarters since. The position peaked at $202M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Rockefeller Capital Management held 911,994 shares of AbbVie worth $198M as of Q1 2026.
- Rockefeller Capital Management bought 28,350 AbbVie shares in Q1 2026, an estimated $6.29M.
- AbbVie made up 0.35% of Rockefeller Capital Management's portfolio in Q1 2026, its #56 holding.
- Rockefeller Capital Management first reported a position in AbbVie in Q1 2018 and has held it in 33 quarters since.
- Rockefeller Capital Management's AbbVie position peaked at $202M in Q4 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.